Iterum Therapeutics Q3 net loss $6.1M; FDA approved ORLYNVAH in October 2024

Iterum Therapeutics plc

2024-Q3 EPS reported -$1.05

Cash, cash equivalents and short-term investments totaled $14.5M at Sept. 30, 2024.
FDA approved ORLYNVAH for uUTI on Oct. 25, 2024; 10 years of GAIN Act exclusivity.
Net loss Q3 2024 was $6.1M vs $3.9M in Q3 2023; non-GAAP net loss $4.8M vs $15.7M.
R&D expenses fell to $3.1M from $14.9M due to completion of REASSURE trial enrollment.
Company seeking strategic partners for ORLYNVAH; cash expected to fund into 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.